Biotech · Private company
CureVac
Track this companyFree. Adds CureVac to your Dealase workspace and tells you when its record changes.
Clinical trials50 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- CV09070101 mRNA vaccine (CVHNLC) 100 µgPhase 1 · Squamous NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- CV09070101 mRNA vaccine (CVHNLC) 200 µgPhase 1 · Squamous NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- CV09070101 mRNA vaccine (CVHNLC) 400 µgPhase 1 · Squamous NSCLCClinicalTrials.gov · fetched Nov 12, 2026
- CV09070101 mRNA vaccine (CVHNLC) 50 µgPhase 1 · Squamous NSCLCClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)PHASE1 · WITHDRAWN · started Jul 30, 2025ClinicalTrials.gov NCT07073183 · fetched Nov 12, 2026
- A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy AdultsPHASE2 · COMPLETED · started Aug 1, 2023ClinicalTrials.gov NCT05960097 · fetched Nov 12, 2026
- A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older AdultsPHASE1_PHASE2 · COMPLETED · started Apr 27, 2023ClinicalTrials.gov NCT05823974 · fetched Nov 12, 2026
- Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult ParticipantsPHASE1 · COMPLETED · started Mar 24, 2022ClinicalTrials.gov NCT05260437 · fetched Nov 12, 2026
- Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLCPHASE1_PHASE2 · COMPLETED · started Dec 20, 2017ClinicalTrials.gov NCT03164772 · fetched Nov 12, 2026